Interferon α for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus

Clinical Infectious Diseases

Volumn 23, Issue 3, 1996, Pages 585-591

  Soriano, V ^a   Garcia Samaniego J ^a   Bravo, R ^a   Gonzalez J ^a   Castro, A ^a   Castilla, J ^a   Martinez Odriozola P ^a   Colmenero, M ^a   Carballo, E ^a   Suarez D ^a   Rodriguez Pinero F J ^a   Moreno, A ^a   Del Romero, J ^a   Pedreira, J ^a   Gonzalez Lahoz J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; VIREMIA;

EID: 19244364599     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.3.585     Document Type: Article

References (13)

1. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991;4:770-6.
2. Vella S, Giuliano M, Pezzotti P, et al. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA 1992;267:1232-6.
3. Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992;326:1037-42.
4. Gradon JD, Timone JG, Schnittman SM. Emergence of unusual opportunistic pathogens in AIDS: a review. Clin Infect Dis 1992;15:134-57.
5. Soriano V, Valencia E, Laguna F, González-Lahoz J. High morbidity and mortality associated with non-AIDS defining conditions in HIV-infected patients in Spain [letter]. Genitourin Med 1994;70:355-6.
6. Haverkos HW, Lange WR. Serious infections other than human immunodeficiency virus among intravenous drug abusers. J Infect Dis 1990;161:894-902.
7. Soriano V, García-Samaniego J, Bravo R, et al. Morbilidad y mortalidad asociadas a hepatopatía cronica viral en pacientes infectados por el virus de la inmunodeficiencia humana. Med Clin (Barc) 1995;104:641-4.
8. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Sem Liver Dis 1995;15:82-91.
9. Marcellin P, Boyer N, Giostra E, et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13:393-7.
10. Boyer N, Marcellin P, Degott C, et al. Recombinant interferon-α for chronic hepatitis C in patients positive for antibody to human immunodeficiency viras. J Infect Dis 1992;165:723-6.
11. Marriott E, Navas S, del Romero J, et al. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients. J Med Virol 1993;40:107-11.
12. Knodell RG, Ishak KG, Black WC. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
13. Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-102.